Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease

Clinical and Experimental Gastroenterology

Volumn 7, Issue , 2014, Pages 307-328

  Levitt, David G ^a   Levitt, Michael D ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Albumin; Conjugation; Diazo; Liver; Rotor

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; ORGANIC ANION TRANSPORTER;

BILE LEVEL; BILIRUBIN BINDING; BILIRUBIN BLOOD LEVEL; BILIRUBIN METABOLISM; BILIRUBIN TRANSPORT; BINDING AFFINITY; CELL TRANSPORT; CHOLESTASIS; CHROMATOGRAPHY; CRIGLER NAJJAR SYNDROME; DUBIN JOHNSON SYNDROME; ENTEROHEPATIC CIRCULATION; EXCRETION; EXTRAHEPATIC BILE DUCT OBSTRUCTION; GILBERT DISEASE; GLUCURONIDATION; HEMOLYSIS; HEPATITIS; HOMEOSTASIS; HUMAN; HYPERBILIRUBINEMIA; INBORN ERROR OF METABOLISM; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER CIRRHOSIS; LIVER LEVEL; NEWBORN JAUNDICE; NONHUMAN; QUANTITATIVE ANALYSIS; REVIEW; ROTOR SYNDROME;

EID: 84908156701     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S64283     Document Type: Review

References (157)

1. Papavramidou N, Fee E, Christopoulou-Aletra H. Jaundice in the Hippocratic Corpus. J Gastrointest Surg. 2007;11(12):1728–1731.
2. van den Bergh AAH, Muller P. Über eine direkte und eine indirekte Diazoreaktion auf Bilirubin [About a direct and an indirect diazo reac­tion to bilirubin]. Biochem Z. 1916;77:90–103. German.
3. Billling BH, Cole PG, Lathe GH. The excretion of bilirubin as a dig­lucuronide giving the direct van den Bergh reaction. Biochem J. 1957; 65(4):774–784.
4. Talafant E. Properties and composition of the bile pigment giving a direct diazo reaction. Nature. 1956;178(4528):312.
5. Blanckaert N, Fevery J. Physiology and pathophysiology of bilirubin metabolism. In: Zakim D, Boyer TD, editors. Hepatology: A Textbook of Liver Disease. Vol 1. 2nd ed. Philadelphia, PA: WB Saunders; 1990:254–302.
6. Roy-Chowdhury J, Roy-Chowdhury N. Bilirubin metabolism and its disorders. In: Boyer TD, Manns MP, Sanyal AJ, Zakim D, editors. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. 6th ed. Philadelphia, PA: Saunders Elsevier; 2012:1079–1109.
7. Mitlyng BL, Chandrashekhar Y, Furne JK, Levitt MD. Use of breath carbon monoxide to measure the influence of prosthetic heart valves on erythrocyte survival. Am J Cardiol. 2006;97(9):1374–1376.
8. Mitlyng BL, Singh JA, Furne JK, Ruddy J, Levitt MD. Use of breath carbon monoxide measurements to assess erythrocyte survival in sub­jects with chronic diseases. Am J Hematol. 2006;81(6):432–438.
9. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. 2007;8(10):766–775.
10. Mancuso C, Navarra P, Preziosi P. Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010;113(3):563–575.
11. Rochette L, Cottin Y, Zeller M, Vergely C. Carbon monoxide: mechanisms of action and potential clinical implications. Pharmacol Ther. 2013;137(2):133–152.
12. Vítek L, Schwertner HA. The heme catabolic pathway and its protec­tive effects on oxidative stress-mediated diseases. Adv Clin Chem. 2007;43:1–57.
13. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043–1046.
14. Mancuso C, Barone E. The heme oxygenase/biliverdin reductase path­way in drug research and development. Curr Drug Metab. 2009;10(6): 579–594.
15. Gibbs PE, Tudor C, Maines MD. Biliverdin reductase: more than a namesake – the reductase, its Peptide fragments, and biliverdin regu­late activity of the three classes of protein kinase C. Front Pharmacol. 2012;3:31.
16. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99(25):16093–16098.
17. Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular anti­oxidant protection by biliverdin reductase. J Biol Chem. 2009;284(43): 29251–29259.
18. McDonagh AF. The biliverdin-bilirubin antioxidant cycle of cellular protection: missing a wheel? Free Radic Biol Med. 2010;49(5):814–820.
19. Barone E, Trombino S, Cassano R, et al. Characterization of the S-denitrosylating activity of bilirubin. J Cell Mol Med. 2009;13(8B): 2365–2375.
20. Mancuso C, Bonsignore A, Capone C, Di Stasio E, Pani G. Albumin-bound bilirubin interacts with nitric oxide by a redox mechanism. Antioxid Redox Signal. 2006;8(3–4):487–494.
21. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys. 1998;352(2):165–174.
22. Ghem C, Sarmento-Leite RE, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an estab­lished coronary artery disease. Int Heart J. 2010;51(2):86–91.
23. Tell G, Gustincich S. Redox state, oxidative stress, and molecular mechanisms of protective and toxic effects of bilirubin on cells. Curr Pharm Des. 2009;15(25):2908–2914.
24. Turfan M, Duran M, Poyraz F, et al. Inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease. Coron Artery Dis. 2013;24(1):29–32.
25. Vítek L, Jirsa M, Brodanová M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160(2):449–456.
26. Bonnett R, Davies JE, Hursthouse MB, Sheldrick GM. The struc­ture of bilirubin. Proc R Soc Lond B Biol Sci. 1978;202(1147):249–268.
27. Brodersen R, Stern L. Binding of bilirubin to albumin. Crit Rev Clin Lab Sci. 1980;11(4):305–399.
28. Hahm JS, Ostrow JD, Mukerjee P, Celic L. Ionization and self-association of unconjugated bilirubin, determined by rapid solvent partition from chloroform, with further studies of bilirubin solubility. J Lipid Res. 1992;33(8):1123–1137.
29. Wennberg RP. The blood-brain barrier and bilirubin encephalopathy. Cell Mol Neurobiol. 2000;20(1):97–109.
30. Zucker SD, Goessling W, Hoppin AG. Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepato­cyte membranes. J Biol Chem. 1999;274(16):10852–10862.
31. Levitt DG. The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003;3:3.
32. Simons PC, Jagt DL. Bilirubin binding to human liver ligandin (glutathione S-transferase). J Biol Chem. 1980;255(10):4740–4744.
33. Scheidt PC, Mellits ED, Hardy JB, Drage JS, Boggs TR. Toxicity to bilirubin in neonates: infant development during first year in rela­tion to maximum neonatal serum bilirubin concentration. J Pediatr. 1977;91(2):292–297.
34. Crigler JF Jr, Najjar VA. Congenital familiar nonhemolyltic jaundice with kernicterus. Pediatrics. 1952;10:169–180.
35. Watchko JF. Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns. Neuromolecular Med. 2006;8(4): 513–529.
36. Mancuso C, Capone C, Ranieri SC, et al. Bilirubin as an endogenous modulator of neurotrophin redox signaling. J Neurosci Res. 2008; 86(10):2235–2249.
37. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev. 1981;33(1):17–53.
38. Berk PD, Howe RB, Bloomer JR, Berlin NI. Studies of bilirubin kinetics in normal adults. J Clin Invest. 1969;48(11):2176–2190.
39. Levitt DG. PKQuest: capillary permeability limitation and plasma pro­tein binding – application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics. BMC Clin Pharmacol. 2002;2:7.
40. Levitt DG. PKQuest_Java: free, interactive physiologically based pharmacokinetic software package and tutorial. BMC Res Notes. 2009;2:158.
41. Blanckaert N, Heirwegh KPM. Analysis and preparation of bilirubins and biliverdins. In: Ostrow JD, editor. Bile Pigments and Jaundice. New York, NY: Marcel Dekker, Inc.; 1986:31–79.
42. Pieper-Bigelow C, Eckfeldt J, Levitt MD. Sensitivity of HPLC and con­ventional bilirubin measurements in the detection of early cholestasis. J Lab Clin Med. 1995;125(5):654–661.
43. Doumas BT, Wu TW. The measurement of bilirubin fractions in serum. Crit Rev Clin Lab Sci. 1991;28(5–6):415–445.
44. Dutt MK, Murphy GM, Thompson RP. Unconjugated bilirubin in human bile: the nucleating factor in cholesterol cholelithiasis? J Clin Pathol. 2003;56(8):596–598.
45. Fulop M, Sandson J, Brazeau P. Dialyzability, protein binding, and renal excretion of plasma conjugated bilirubin. J Clin Invest. 1965; 44:666–680.
46. Cameron JL, Stafford ES, Schnaufer L, Iber FL. Bilirubin excretion in the dog. J Surg Res. 1963;3:39–42.
47. Fulop M, Brazeau P. Impaired renal function exaggerates hyperbilirubine­mia in bile duct-ligated dogs. Am J Dig Dis. 1970;15(12):1067–1072.
48. Cameron JL, Filler RM, Iber FL, Abei T, Randolph JG. Metabolism and excretion of C14-labeled bilirubin in children with biliary atresia. N Engl J Med. 1966;274(5):231–236.
49. Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med. 1983;309(3):147–150.
50. Beeken WL, Volwiler W, Goldsworthy PD, et al. Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest. 1962;41:1312–1333.
51. Fevery J. Bilirubin in clinical practice: a review. Liver Int. 2008;28(5): 592–605.
52. Hardman JG, Limbird LE, editors. Goodman and Gilman’s The Phar­macological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill; 2001.
53. Guillemette C, Lévesque E, Harvey M, Bellemare J, Menard V. UGT genomic diversity: beyond gene duplication. Drug Metab Rev. 2010;42(1):24–44.
54. Bock KW. Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms respon­sible for interindividual variation of UGT levels. Biochem Pharmacol. 2010;80(6):771–777.
55. Burchell B, Blanckaert N. Bilirubin mono- and di-glucuronide formation by purified rat liver microsomal bilirubin UDP-glucuronyltransferase. Biochem J. 1984;223(2):461–465.
56. Skierka JM, Kotzer KE, Lagerstedt SA, O’Kane DJ, Baudhuin LM. UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia. J Pediatr. 2013;162(6):1146–1152, 1152. e1–e2.
57. Fevery J, Blanckaert N, Heirwegh KP, Préaux AM, Berthelot P. Unconjugated bilirubin and an increased proportion of bilirubin monoconjugates in the bile of patients with Gilbert’s syndrome and Crigler-Najjar disease. J Clin Invest. 1977;60(5):970–979.
58. McDonagh AF. Controversies in bilirubin biochemistry and their clini­cal relevance. Semin Fetal Neonatal Med. 2010;15(3):141–147.
59. Wang P, Kim RB, Chowdhury JR, Wolkoff AW. The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. J Biol Chem. 2003;278(23):20695–20699.
60. White JK, Gerdin AK, Karp NA, et al. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell. 2013;154(2):452–464.
61. Iga T, Eaton DL, Klaassen CD. Uptake of unconjugated bilirubin by isolated rat hepatocytes. Am J Physiol. 1979;236(1):C9–C14.
62. Black M, Billing BH. Hepatic bilirubin udp-glucuronyl transferase activity in liver disease and gilbert’s syndrome. N Engl J Med. 1969;280(23):1266–1271.
63. Chowdhury JR, Chowdhury NR, Wu G, Shouval R, Arias IM. Bilirubin mono- and diglucuronide formation by human liver in vitro: assay by high-pressure liquid chromatography. Hepatology. 1981;1(6):622–627.
64. Zhou J, Tracy TS, Remmel RP. Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos. 2010;38(11):1907–1911.
65. Crone C. The permeability of capillaries in various organs as deter­mined by use of the ‘indicator diffusion’ method. Acta Physiol Scand. 1963;58:292–305.
66. Zelenka J, Lenícek M, Muchová L, et al. Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1):37–42.
67. Muchova L, Vanova K, Zelenka J, et al. Bile acids decrease intracel­lular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress. J Cell Mol Med. 2011;15(5):1156–1165.
68. Wolkoff AW, Ketley JN, Waggoner JG, Berk PD, Jakoby WB. Hepatic accumulation and intracellular binding of conjugated bilirubin. J Clin Invest. 1978;61(1):142–149.
69. Wolkoff AW, Goresky CA, Sellin J, Gatmaitan Z, Arias IM. Role of ligandin in transfer of bilirubin from plasma into liver. Am J Physiol. 1979;236(6):E638–E648.
70. Oie S, Levy G. Effect of salicylic acid on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia. J Pharm Sci. 1979;68(1):1–6.
71. Oie S, Levy G. Effect of sulfisoxazole on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia. J Pharm Sci. 1979;68(1):6–9.
72. Fukui M, Tanaka M, Yamazaki M, et al. Low serum bilirubin concen­tration in haemodialysis patients with Type 2 diabetes. Diabet Med. 2011;28(1):96–99.
73. Tsutsumi Y, Maruyama T, Takadate A, Shimada H, Otagiri M. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron. 2000;85(1):60–64.
74. Oie S, Lowenthal DT, Levy G. Protein binding of bilirubin in plasma of anephric patients. J Dial. 1980;4(2–3):91–100.
75. Tsutsumi Y, Maruyama T, Takadate A, Goto M, Matsunaga H, Otagiri M. Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm Res. 1999; 16(6):916–923.
76. Weisiger RA. Dissociation from albumin: a potentially rate-limiting step in the clearance of substances by the liver. Proc Natl Acad Sci U S A. 1985;82(5):1563–1567.
77. Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics. 2002;12(8):635–645.
78. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005; 33(7):1027–1035.
79. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A. 2001;98(22): 12671–12676.
80. Crawford JM, Ransil BJ, Narciso JP, Gollan JL. Hepatic microsomal bilirubin UDP-glucuronosyltransferase. The kinetics of bilirubin mono- and diglucuronide synthesis. J Biol Chem. 1992;267(24):16943–16950.
81. Schmid R, Hammaker L. Metabolism and disposition of C14-bilirubin in congenital nonhemolytic jaundice. J Clin Invest. 1963;42: 1720–1734.
82. Kotal P, Van der Veere CN, Sinaasappel M, et al. Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia. Pediatr Res. 1997;42(2):195–200.
83. Gordon ER, Shaffer EA, Sass-Kortsak A. Bilirubin secretion and conjujation in the Crigler-Najjar syndrome type II. Gastroenterology. 1976;70(5 PT.1):761–765.
84. Sinaasappel M, Jansen PL. The differential diagnosis of Crigler-Najjar disease, types 1 and 2, by bile pigment analysis. Gastroenterology. 1991;100(3):783–789.
85. Hafkamp AM, Havinga R, Ostrow JD, et al. Novel kinetic insights into treatment of unconjugated hyperbilirubinemia: phototherapy and orlistat treatment in Gunn rats. Pediatr Res. 2006;59(4 Pt 1):506–512.
86. Van Der Veere CN, Schoemaker B, Bakker C, Van Der Meer R, Jansen PL, Elferink RP. Influence of dietary calcium phosphate on the dis­position of bilirubin in rats with unconjugated hyperbilirubinemia. Hepatology. 1996;24(3):620–626.
87. Van der Veere CN, Jansen PL, Sinaasappel M, et al. Oral calcium phosphate: a new therapy for Crigler-Najjar disease? Gastroenterology. 1997;112(2):455–462.
88. Levitt DG. Quantitation of small intestinal permeability during normal human drug absorption. BMC Pharmacol Toxicol. 2013;14:34.
89. Ihara H, Hashizume N, Shimizu N, Aoki T. Threshold concentration of unbound bilirubin to induce neurological deficits in a patient with type I Crigler-Najjar syndrome. Ann Clin Biochem. 1999;36(Pt 3): 347–352.
90. Blaschke TF, Berk PD, Scharschmidt BF, Guyther JR, Vergalla JM, Waggoner JG. Crigler-Najjar syndrome: an unusual course with development of neurologic damage at age eighteen. Pediatr Res. 1974;8(5):573–590.
91. Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect. Gastroenterology. 1997;112(6):2099–2103.
92. Jansen PL. Diagnosis and management of Crigler-Najjar syndrome. Eur J Pediatr. 1999;158 Suppl 2:S89–S94.
93. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007;453(5):643–659.
94. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P. ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab Rev. 2010;42(3):402–436.
95. Oyabu H, Tabata M, Nakayama F. Nonbacterial transformation of bilirubin in bile. Dig Dis Sci. 1987;32(8):809–816.
96. Duvaldestin P, Mahu JL, Metreau JM, Arondel J, Preaux AM, Berthelot P. Possible role of a defect in hepatic bilirubin glucuroni­dation in the initiation of cholesterol gallstones. Gut. 1980;21(8):650–655.
97. Trotman BW, Ostrow JD, Soloway RD. Pigment vs cholesterol cholelithiasis: comparison of stone and bile composition. Am J Dig Dis. 1974;19(7):585–590.
98. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology. 1997;25(6):1539–1542.
99. Shani M, Seligsohn U, Gilon E, Sherba C, Adam A. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med. 1970;39:549–567.
100. Verkade HJ, Havinga R, Gerding A, Vonk RJ, Kuipers F. Mechanism of bile acid-induced biliary lipid secretion in the rat: effect of conju­gated bilirubin. Am J Physiol. 1993;264(3 Pt 1):G462–G469.
101. Nishida T, Gatmaitan Z, Roy-Chowdhry J, Arias IM. Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicu­lar membrane vesicles. Demonstration of defective ATP-dependent transport in rats (TR-) with inherited conjugated hyperbilirubinemia. J Clin Invest. 1992;90(5):2130–2135.
102. van de Steeg E, Wagenaar E, van der Kruijssen CM, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest. 2010;120(8):2942–2952.
103. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci. 2012;33(2):100–108.
104. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165(5):1260–1287.
105. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001;276(13):9626–9630.
106. van de Steeg E, Stránecký V, Hartmannová H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest. 2012;122(2):519–528.
107. Arias IM. Studies of chronic familial non-hemolytic jaundice with conjugated bilirubin in the serum with and without an unidentified pigment in the liver cells. Am J Med. 1961;31(4):510–518.
108. Kawasaki H, Kimura N, Irisa T, Hirayama C. Dye clearance studies in Rotor’s syndrome. Am J Gastroenterol. 1979;71(4):380–388.
109. Wolpert E, Pascasio FM, Wolkoff AW, Arias IM. Abnormal sul­fobromophthalein metabolism in Rotor’s syndrome and obligate heterozygotes. N Engl J Med. 1977;296(19):1099–1101.
110. Butt HR, Anderson VE, Foulk WT, Baggenstoss AH, Schoenfield LJ, Dickson ER. Studies of chronic idiopathic jaundice (Dubin-Johnson syndrome). II. Evaluation of a large family with the trait. Gastroenterology. 1966;51(5):619–630.
111. Zelcer N, van de Wetering K, Hillebrand M, et al. Mice lacking multi­drug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A. 2005;102(20):7274–7279.
112. Manautou JE, de Waart DR, Kunne C, et al. Altered disposition of acet­aminophen in mice with a disruption of the Mrp3 gene. Hepatology. 2005;42(5):1091–1098.
113. Chai J, He Y, Cai SY, et al. Elevated hepatic multidrug resis­tance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology. 2012;55(5):1485–1494.
114. Kruh GD, Belinsky MG, Gallo JM, Lee K. Physiological and phar­macological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev. 2007;26(1):5–14.
115. Arias IM, Johnson L, Wolfson S. Biliary excretion of injected con­jugated and unconjugated bilirubin by normal and Gunn rats. Am J Physiol. 1961;200:1091–1094.
116. Shupeck M, Wolkoff AW, Scharschmidt BF, Waggoner JG, Berk PD. Studies of the kinetics of purified conjugated bilirubin-3H in the rat. Am J Gastroenterol. 1978;70(3):259–264.
117. Tisdale WA, Klatskin G, Kinsella ED. The significance of the direct-reacting fraction of serum bilirubin in hemolytic jaundice. Am J Med. 1959;26(2):214–227.
118. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009;50(12):2340–2357.
119. Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev. 2010;42(3):437–445.
120. Hayashi H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11): trafficking and sorting disturbances. Curr Mol Pharmacol. 2013;6(2): 95–103.
121. Jessner W, Zsembery A, Graf J. Transcellular water transport in hepatobiliary secretion and role of aquaporins in liver. Wien Med Wochenschr. 2008;158(19–20):565–569.
122. Barnhart JL, Combes B. Erythritol and mannitol clearances with taurocholate and secretin-induced cholereses. Am J Physiol. 1978;234(2):E146–E156.
123. Jaeschke H, Krell H, Pfaff E. Quantitative estimation of transcellular and paracellular pathways of biliary sucrose in isolated perfused rat liver. Biochem J. 1987;241(3):635–640.
124. Carlson E, Zukoski CF, Campbell J, Chvapil M. Morphologic, bio­physical, and biochemical consequences of ligation of the common biliary duct in the dog. Am J Pathol. 1977;86(2):301–320.
125. De Vos R, Desmet VJ. Morphologic changes of the junctional complex of the hepatocytes in rat liver after bile duct ligation. Br J Exp Pathol. 1978;59(2):220–227.
126. Metz J, Aoki A, Merlo M, Forssmann WG. Morphological alterations and functional changes of interhepatocellular junctions induced by bile duct ligation. Cell Tissue Res. 1977;182(3):299–310.
127. Sieg A, Konig R, Ullrich D, Fevery J. Subfractionation of serum bilirubins by alkaline methanolysis and thin-layer chromatography. An aid in the differential diagnosis of icteric diseases. J Hepatol. 1990;11(2):159–164.
128. Basso D, Fabris C, Plebani M, et al. Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. Clin Investig. 1992;70(1):49–54.
129. Georgiev P, Jochum W, Heinrich S, et al. Characterization of time-related changes after experimental bile duct ligation. Br J Surg. 2008;95(5):646–656.
130. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology. 1999;117(3):669–677.
131. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272–276.
132. Delemos AS, Friedman LS. Systemic causes of cholestasis. Clin Liver Dis. 2013;17(2):301–317.
133. Bjhornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis. 2013;17(2):191–209.
134. Brites D, Rodrigues CM, van-Zeller H, Brito A, Silva R. Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal. Eur J Obstet Gynecol Reprod Biol. 1998;80(1):31–38.
135. Castaño G, Lucangioli S, Sookoian S, et al. Bile acid profiles by capil­lary electrophoresis in intrahepatic cholestasis of pregnancy. Clin Sci (Lond). 2006;110(4):459–465.
136. Abu-Hayyeh S, Papacleovoulou G, Lövgren-Sandblom A, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatology. 2013;57(2):716–726.
137. Lester R, Schmid R. Intestinal absorption of bile pigments. II. Bilirubin absorption in man. N Engl J Med. 1963;269:178–182.
138. Vítek L, Kotal P, Jirsa M, et al. Intestinal colonization leading to fecal urobilinoid excretion may play a role in the pathogenesis of neonatal jaundice. J Pediatr Gastroenterol Nutr. 2000;30(3):294–298.
139. Gourley GR, Arend RA. beta-Glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet. 1986;1(8482):644–646.
140. Poland RL, Odell GB. Physiologic jaundice: the enterohepatic circula­tion of bilirubin. N Engl J Med. 1971;284(1):1–6.
141. Felsher BF, Carpio NM. Caloric intake and unconjugated hyperbili­rubinemia. Gastroenterology. 1975;69(1):42–47.
142. Lundh B, Johansson MB, Mercke C, Cavallin-Stahl E. Enhancement of heme catabolism by caloric restriction in man. Scand J Clin Lab Invest. 1972;30(4):421–427.
143. Bensinger TA, Maisels MJ, Carlson DE, Conrad ME. Effect of low caloric diet on endogenous carbon monoxide production: normal adults and Gilbert’s syndrome. Proc Soc Exp Biol Med. 1973;144(2):417–419.
144. Gollan JL, Bateman C, Billing BH. Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert’s syndrome. Gut. 1976;17(5):335–340.
145. Gärtner U, Goeser T, Wolkoff AW. Effect of fasting on the uptake of bilirubin and sulfobromophthalein by the isolated perfused rat liver. Gastroenterology. 1997;113(5):1707–1713.
146. Kotal P, Vítek L, Fevery J. Fasting-related hyperbilirubinemia in rats: the effect of decreased intestinal motility. Gastroenterology. 1996;111(1):217–223.
147. Fevery J. Fasting hyperbilirubinemia: unraveling the mechanism involved. Gastroenterology. 1997;113(5):1798–1800.
148. Brink MA, Mendez-Sanchez N, Carey MC. Bilirubin cycles enterohepatically after ileal resection in the rat. Gastroenterology. 1996;110(6):1945–1957.
149. Thistle JL, Hofmann AF. Efficacy and specificity of chenode­oxycholic acid therapy for dissolving gallstones. N Engl J Med. 1973;289(13):655–659.
150. Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the US population: gender effect and inverse correlation with colorectal cancer. Hepatology. 2004;40(4):827–835.
151. Raedsch R, Stiehl A, Gundert-Remy U, et al. Hepatic secretion of bilirubin and biliary lipids in patients with alcoholic cirrhosis of the liver. Digestion. 1983;26(2):80–88.
152. Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest. 1960;39:592–600.
153. Branch RA, James JA, Read AE. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease. Clin Pharmacol Ther. 1976;20(1):81–89.
154. Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med. 1975;83(5):632–638.
155. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231.
156. Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.
157. Fulks M, Stout RL, Dolan VF. Mortality associated with bilirubin levels in insurance applicants. J Insur Med. 2009;41(1):49–53.